Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Sean Wharton, Lilian Raiber, Kristin J Serodio, Jasmine Lee & Rebecca AG Christensen. (2018) Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 11, pages 427-438.
Read now
Read now
Kaida Jiang, Lingjiang Li, Xueyi Wang, Maosheng Fang, Jianfei Shi, Qiuyun Cao, Jincai He, Jinan Wang, Weihao Tan & Cuili Hu. (2017) Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population. Neuropsychiatric Disease and Treatment 13, pages 515-526.
Read now
Read now
Jong-Hyun Jeong, Won-Myong Bahk, Young Sup Woo, Kyung-Uk Lee, Do Hoon Kim, Moon-Doo Kim, Won Kim, Jong-Chul Yang & Kwang Heun Lee. (2015) Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study. Neuropsychiatric Disease and Treatment 11, pages 2557-2564.
Read now
Read now
Zeynep Yilmaz, Alessandro Ceschi, Christine Rauber-Lüthy, Oliver Sauer, Uwe Stedtler, Dagmar Prasa, Carola Seidel, Elisabeth Hackl, Petra Hoffmann-Walbeck, Gabriela Gerber-Zupan, Kathrin Bauer, Hugo Kupferschmidt, Gerd-Achim Kullak-Ublick & Martin Wilks. (2010) Escitalopram causes fewer seizures in human overdose than citalopram. Clinical Toxicology 48:3, pages 207-212.
Read now
Read now
Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella & Felipe Fregni. (2010) Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Review of Medical Devices 7:1, pages 67-97.
Read now
Read now
Clinton D Kilts, Alan G Wade, Henning F Andersen & Thomas E Schlaepfer. (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy 10:6, pages 927-936.
Read now
Read now
SS Stamouli, A Yfantis, E Lamboussis, A Liakouras, V Lagari, M Tzanakaki, D Giailoglou, M Legault & IA Parashos. (2009) Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opinion on Pharmacotherapy 10:6, pages 937-945.
Read now
Read now
Sidney H. Kennedy, Henning F. Andersen & Michael E. Thase. (2009) Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion 25:1, pages 161-175.
Read now
Read now
Vasilios G. Masdrakis, Panagiotis Oulis, Anastasios V. Kouzoupis, George V. Masdrakis & Constantin R. Soldatos. (2009) Bilateral ankle oedema in a patient taking escitalopram. The World Journal of Biological Psychiatry 10:4-3, pages 939-941.
Read now
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Christophe Lançon, Patrice Verpillat, Lieven Annemans, Nicolas Despiegel & Clément François. (2007) Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. International Journal of Psychiatry in Clinical Practice 11:1, pages 44-52.
Read now
Read now
Michael E Thase. (2006) Managing depressive and anxiety disorders with escitalopram. Expert Opinion on Pharmacotherapy 7:4, pages 429-440.
Read now
Read now
Thomas C. Baghai, Hans-Peter Volz & Hans-Jürgen Möller. (2006) Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. The World Journal of Biological Psychiatry 7:4, pages 198-222.
Read now
Read now
David S. Baldwin. (2006) The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice 10:sup1, pages 31-37.
Read now
Read now
Sidney H. Kennedy. (2006) Current treatment options: relief of symptoms and ultimate recovery. International Journal of Psychiatry in Clinical Practice 10:sup1, pages 22-26.
Read now
Read now
Articles from other publishers (40)
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin & Mingsan Miao. (2023) Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry 23:1.
Crossref
Crossref
Carlos Eduardo Miranda Sousa, Noely Camila Tavares Cavalcanti Bedor, Giovana Damasceno Sousa, Guilherme Henrique Onório Oliveira, Leila Bastos Leal, Danilo Cesar Galindo Bedor, Whocely Victor Castro & Davi Pereira Santana. (2021) Selective LC–MS/MS determination of citalopram enantiomers and application to a pharmacokinetic evaluation of generic and reference formulations. Biomedical Chromatography 36:1.
Crossref
Crossref
Tatiyana Mandal, Laxminarayana Kurady Bairy, Podila Satya Venkata Narasimha Sharma & Vijaya Lakshmi Valaparla. (2021) Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 57:1.
Crossref
Crossref
Xiaoliang Wang, Yimin Fan, Guanjun Li & Huafang Li. (2021) The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. International Clinical Psychopharmacology 36:3, pages 133-139.
Crossref
Crossref
Isaac Ng, H. Karl Greenblatt & David J. Greenblatt. (2016) Stereo-Psychopharmacology: The Case of Citalopram and Escitalopram. Clinical Pharmacology in Drug Development 5:5, pages 331-335.
Crossref
Crossref
Wataru Yamadera, Michiaki Morita, Satoshi Sakamoto, Ayako Kuroda, Hiroshi Itoh & Kazuhiko Nakayama. (2016) Comparison of escitalopram alone and combined with zolpidem in treating major depression and related sleep impairments. Sleep and Biological Rhythms 14:3, pages 303-308.
Crossref
Crossref
David F. Lehmann & Sarabeth Wojnowicz. (2015) The Evergreening of Biopharmaceuticals: Time to Defoliate. The Journal of Clinical Pharmacology 56:4, pages 383-389.
Crossref
Crossref
Ayman Akil, Robert R. Bies, Bruce G. Pollock, Dimitrios Avramopoulos, D. P. Devanand, Jacobo E. Mintzer, Anton P. Porsteinsson, Lon S. Schneider, Daniel Weintraub, Jerome Yesavage, David M. Shade & Constantine G. Lyketsos. (2015) A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics 43:1, pages 99-109.
Crossref
Crossref
Jacob P. R. Jacobsen, Per Plenge, Benjamin D. Sachs, Alan L. Pehrson, Manuel Cajina, Yunzhi Du, Wendy Roberts, Meghan L. Rudder, Prachiti Dalvi, Taylor J. Robinson, Sharon P. O’Neill, King S. Khoo, Connie Sanchez Morillo, Xiaodong Zhang & Marc G. Caron. (2014) The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. Psychopharmacology 231:23, pages 4527-4540.
Crossref
Crossref
Emmanuelle Corruble, Christian de Bodinat, Carole Belaïdi & Guy M. Goodwin. (2013) Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. International Journal of Neuropsychopharmacology 16:10, pages 2219-2234.
Crossref
Crossref
Andrea Cipriani, Marianna Purgato, Toshi A Furukawa, Carlotta Trespidi, Giuseppe Imperadore, Alessandra Signoretti, Rachel Churchill, Norio Watanabe & Corrado Barbui. (2012) Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Crossref
Hye Yoon Park, Byoung-Jo Lee, Jong-Hoon Kim, Jae-Nam Bae & Bong-Jin Hahm. (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 36:2, pages 318-323.
Crossref
Crossref
Dan J. Stein & Ana Garcia Lopez. (2011) Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Advances in Therapy 28:11, pages 1021-1037.
Crossref
Crossref
Stuart Montgomery, Thomas Hansen & Siegfried Kasper. (2010) Efficacy of escitalopram compared to citalopram: a meta-analysis. The International Journal of Neuropsychopharmacology 14:02, pages 261-268.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
Andréa D.E. Zomkowski, Daiane Engel, Nelson H. Gabilan & Ana Lúcia S. Rodrigues. (2010) Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. European Neuropsychopharmacology 20:11, pages 793-801.
Crossref
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
C. Garcia-LealCM Del-Ben, FM Leal, FG Graeff & FS Guimarães. (2009) Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation. Journal of Psychopharmacology 24:5, pages 683-694.
Crossref
Crossref
Gerald Gartlehner, Laura Morgan, Patricia Thieda & Anthony Fleg. (2010) The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. Journal of Clinical Epidemiology 63:2, pages 117-125.
Crossref
Crossref
David S. Baldwin, Dan J. Stein, Ornah T. Dolberg & Borwin Bandelow. (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental 24:4, pages 269-275.
Crossref
Crossref
Andrea Cipriani, Claudio Santilli, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Hugh McGuire, Rachel Churchill & Corrado Barbui. (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Siegfried Kasper, David S. Baldwin, Sara Larsson Lönn & Jean-Philippe Boulenger. (2009) Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology 19:4, pages 229-237.
Crossref
Crossref
Dominick Esposito, Peter Wahl, Gregory Daniel, Michael A. Stoto, M. Haim Erder & Thomas W. Croghan. (2009) Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clinical Therapeutics 31:3, pages 644-656.
Crossref
Crossref
A.G. Wade, T.E. Schlaepfer, H.F. Andersen & C.D. Kilts. (2009) Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43:5, pages 568-575.
Crossref
Crossref
Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, John R Geddes, Julian PT Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, Hugh McGuire, Michele Tansella & Corrado Barbui. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:9665, pages 746-758.
Crossref
Crossref
Pratap Chokka & Mark Legault. (2008) Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial. Depression and Anxiety 25:12, pages E173-E181.
Crossref
Crossref
Yves Lecrubier, Ornah T. Dolberg, Henning F. Andersen & Emmanuelle Weiller. (2007) Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience 258:3, pages 171-178.
Crossref
Crossref
Gerald Gartlehner, Patricia Thieda, Richard A Hansen, Bradley N Gaynes, Angela DeVeaugh-Geiss, Erin E Krebs & Kathleen N Lohr. (2008) Comparative Risk for Harms of Second-Generation Antidepressants. Drug Safety 31:10, pages 851-865.
Crossref
Crossref
Pei-xian Mao, Yi-lang Tang, Feng Jiang, Liang Shu, Xiuling Gu, Ming Li, Mincai Qian, Cui Ma, Philip B. Mitchell & Zhuo-ji Cai. (2008) Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depression and Anxiety 25:1, pages 46-54.
Crossref
Crossref
Johan Lundberg, Jacob Strøyer Christophersen, Kamilla Buchberg Petersen, Henrik Loft, Christer Halldin & Lars Farde. (2007) PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. The International Journal of Neuropsychopharmacology 10:06.
Crossref
Crossref
P. Van Dijck. (2007) Escitalopram, un développement clinique complet. L'Encéphale 33, pages 134-139.
Crossref
Crossref
David S Baldwin, Elin Heldbo Reines, Christina Guiton & Emmanuelle Weiller. (2016) Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy 41:10, pages 1583-1592.
Crossref
Crossref
Nikolas Klein, Julia Sacher, Thomas Geiss-Granadia, Nilufar Mossaheb, Trawat Attarbaschi, Rupert Lanzenberger, Christoph Spindelegger, Alexander Holik, Susanne Asenbaum, Robert Dudczak, Johannes Tauscher & Siegfried Kasper. (2007) Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology 191:2, pages 333-339.
Crossref
Crossref
David S. Baldwin, James A. Cooper, Anna K.T. Huusom & Ian Hindmarch. (2006) A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Clinical Psychopharmacology 21:3, pages 159-169.
Crossref
Crossref
María Velasco, Luis Salvador, Carmelo Juárez & Fernando Antoñanzas. (2013) Análisis de coste-efectividad de escitalopram comparado con citalopram en el tratamiento de pacientes con depresión mayor grave. PharmacoEconomics Spanish Research Articles 3:2, pages 63-73.
Crossref
Crossref
Siegfried Kasper, Christian Spadone, Patrice Verpillat & Jules Angst. (2006) Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. International Clinical Psychopharmacology 21:2, pages 105-110.
Crossref
Crossref
David Murdoch & Susan J Keam. (2006) Spotlight on Escitalopram in the Management of Major Depressive Disorder1. CNS Drugs 20:2, pages 167-170.
Crossref
Crossref
&NA;. (2005) Escitalopram is an effective option for managing major depressive disorder in adults. Drugs & Therapy Perspectives 21:12, pages 1-5.
Crossref
Crossref